HealthEquity, Inc. (NASDAQ:HQY – Get Free Report) has been given an average rating of “Buy” by the twelve research firms that are presently covering the firm, MarketBeat Ratings reports. Twelve analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $103.83.
Several analysts have commented on HQY shares. Barrington Research restated an “outperform” rating and issued a $105.00 price target on shares of HealthEquity in a report on Friday, September 20th. KeyCorp boosted their target price on HealthEquity from $95.00 to $100.00 and gave the stock an “overweight” rating in a report on Wednesday, June 5th. Raymond James boosted their target price on HealthEquity from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Friday, June 7th. JMP Securities reiterated a “market outperform” rating and set a $105.00 target price on shares of HealthEquity in a report on Wednesday, September 4th. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on HealthEquity from $102.00 to $103.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th.
Check Out Our Latest Report on HealthEquity
Insider Buying and Selling at HealthEquity
Institutional Investors Weigh In On HealthEquity
Large investors have recently added to or reduced their stakes in the stock. GM Advisory Group LLC grew its stake in shares of HealthEquity by 300.8% in the fourth quarter. GM Advisory Group LLC now owns 120,355 shares of the company’s stock worth $7,980,000 after purchasing an additional 90,329 shares in the last quarter. Forest Hill Capital LLC bought a new position in shares of HealthEquity in the fourth quarter worth $2,021,000. Norges Bank bought a new position in shares of HealthEquity in the fourth quarter worth $43,482,000. Vanguard Group Inc. grew its stake in shares of HealthEquity by 1.7% in the first quarter. Vanguard Group Inc. now owns 8,768,632 shares of the company’s stock worth $715,783,000 after purchasing an additional 149,133 shares in the last quarter. Finally, Diversify Advisory Services LLC bought a new position in shares of HealthEquity in the first quarter worth $7,828,000. 99.55% of the stock is owned by institutional investors and hedge funds.
HealthEquity Trading Down 1.9 %
NASDAQ:HQY opened at $80.27 on Friday. The company has a market capitalization of $6.98 billion, a PE ratio of 87.25, a price-to-earnings-growth ratio of 1.25 and a beta of 0.52. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.51. HealthEquity has a 52-week low of $61.81 and a 52-week high of $88.26. The stock has a fifty day simple moving average of $76.42 and a 200-day simple moving average of $79.21.
HealthEquity (NASDAQ:HQY – Get Free Report) last announced its earnings results on Tuesday, September 3rd. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.16. HealthEquity had a net margin of 9.61% and a return on equity of 9.01%. The firm had revenue of $299.93 million during the quarter, compared to the consensus estimate of $284.48 million. On average, equities research analysts expect that HealthEquity will post 2.25 earnings per share for the current fiscal year.
HealthEquity Company Profile
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
See Also
- Five stocks we like better than HealthEquity
- Do ETFs Pay Dividends? What You Need to Know
- Why Lennar Stock Could Be the Best Play in the Housing Market
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- 2 Energy Stocks Fueling the AI Datacenter Boom
- How is Compound Interest Calculated?
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.